Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.

Posted by rob on December 22, 2005 under Uncategorized | Be the First to Comment

Park J, Kim S, Oh JK, Kim JY, Yoon SS, Lee D, Kim Y

J Biochem Mol Biol. 2005 Nov 30; 38(6): 725-38

Resistance to imatinib mesylate (also known as Gleevec, Glivec, and STI571) often becomes a barrier to the treatment of chronic myelogenous leukemia (CML). In order to identify markers of the action of imatinib mesylate, we used a mass spectrometry approach to compare protein expression profiles in human leukemia cells (K562) and in imatinib mesylate-resistant human leukemia cells (K562-R) in the presence and absence of imatinib mesylate. We identified 118 differentially regulated proteins in these two leukemia cell-lines, with and without a 1 microM imatinib mesylate challenge. Nine proteins of unknown function were discovered. This is the first comprehensive report regarding differential protein expression in imatinib mesylate-treated CML cells.

Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.